Last reviewed · How we verify

Clover Biopharmaceuticals AUS Pty — Portfolio Competitive Intelligence Brief

Clover Biopharmaceuticals AUS Pty pipeline: 1 marketed, 0 filed, 3 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 3 Phase 3 1 Phase 2 8 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
AREXVY AREXVY marketed Other
CoronaVac Vaccine CoronaVac Vaccine phase 3 Inactivated viral vaccine SARS-CoV-2 spike protein and other viral antigens Immunology / Infectious Disease
Comirnaty Vaccine Comirnaty Vaccine phase 3 mRNA vaccine SARS-CoV-2 spike protein (S protein) Immunology / Infectious Disease
Vaxzevria Vaccine Vaxzevria Vaccine phase 3 Immunology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Pfizer · 2 shared drug classes
  2. Arcturus Therapeutics, Inc. · 1 shared drug class
  3. CSPC Megalith Biopharmaceutical Co.,Ltd. · 1 shared drug class
  4. Bharat Biotech International Limited · 1 shared drug class
  5. BioNTech SE · 1 shared drug class
  6. Boryung Pharmaceutical Co., Ltd · 1 shared drug class
  7. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  8. AJ Vaccines A/S · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Clover Biopharmaceuticals AUS Pty:

Cite this brief

Drug Landscape (2026). Clover Biopharmaceuticals AUS Pty — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/clover-biopharmaceuticals-aus-pty. Accessed 2026-05-16.

Related